The Efficacy of the Combination Therapy with Oral and Topical Mesalazine for Patients with the First Episode of Radiation Proctitis
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Eun Hee Seo Tae Oh Kim Tae Gyoon Kim Hee Rin Joo Jongha Park Seung Ha Park Sung Yeon Yang Young Soo Moon Min Jae Park Dong Yup Ryu
- چاپ و سال / کشور: 2011
Description
Background/Aims Radiation proctitis is a common complication of pelvic radiation for which an optimal treatment remains undetermined. We assessed the efficacy of oral and topical mesalazine combination therapy for patients with naive radiation proctitis. Methods A total of 23 patients with radiation proctitis were enrolled in the study over a period of 2 years. Three of these patients were excluded due to severe bleeding during the study. Twenty patients (mean age 60.3 years; two males, 18 females) were treated with oral mesalazine (3 9 1 g per day) plus a daily mesalazine suppository (1 g per day at bedtime) for 4 weeks. The efficacy of treatment was assessed according to the Subjective Objective Management Analytic (SOMA) scale for alleviation of clinical symptoms of rectal toxicity and sigmoidoscopic findings. Results The mean bleeding score improved significantly from 2.10 to 1.70 (p = 0.002) with mesalazine treatment. However, scores were not improved for pain (0.30–0.20, p = 0.163), tenesmus (0.50–0.45, p = 0.577), or stool frequency (0.35–0.30, p = 0.577). The improvements in the mean telangiectasia score (1.80–1.45, p = 0.005), bleeding point score (1.60–1.05, p\0.001), and friable mucosa score (1.35–1.00, p = 0.005) were all statistically significant. No side-effects were noted in any of the patients. Conclusions The combination of oral and topical mesalazine therapy for radiation proctitis may be a safe and effective treatment for naive radiation proctitis, especially for hemorrhagic proctitis. A large, randomized controlled trial is required to confirm the results of this pilot study.
Dig Dis Sci DOI 10.1007/s10620-011-1637-7 Received: 28 October 2010 / Accepted: 14 February 2011
